GAINESVILLE, Fla., and CAMBRIDGE, Mass., July 07, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC ), a clinical-stage biotechnology company focused on the development of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases with an initial focus on inherited retinal diseases, today announced two encore presentations on the interim safety results in three studies. One of the presentations will focus on interim safety results in two Phase 1/2 dose-escalation clinical trials of AGTC-401 and AGTC-402 in patients with achromatopsia (ACHM) caused by mutations in the CNGB3 and CNGBA3 genes respectively. The other presentation will focus on interim safety results in the ongoing Phase 2 Skyline trial of AGTC-501, a recombinant AAV viral vector-based gene therapy targeting mutations in the RPGR gene in patients with X-linked retinitis pigmentosa (XLRP). Each presentation will be shared during the American Society of Retina Specialists (ASRS) Annual Meeting, taking place July 13-16 in New York City.
"We are honored to join our colleagues in the ophthalmology community, during this important retina meeting, to present data from the exciting gene therapies we are developing at AGTC as potential treatments for both ACHM and XLRP," said Dr. Susan Schneider, Chief Medical Officer of AGTC. "We look forward to sharing future updates as we continue to progress these assets through their respective clinical development paths."
Presentation details are as follows:
Interim Subretinal Gene Therapy Safety Results in Two Phase 1/2 Open-label, Dose-escalation Clinical Trials to Treat Achromatopsia
Presenter: Lejla Vajzovic, MD, FASRS, Assistant Professor of Ophthalmology, Adult and Pediatric Vitreoretinal Surgery and Diseases, Duke University Eye Center, Durham, NC
Session Date/Time: July 16, 2022; 3:35 PM – 4:15 PM ET
Presentation Date/Time: July 16, 2022; 3:57 PM – 4:03 PM ET
Sub-retinal Gene Therapy Drug AGTC-501 for ...
Full story available on Benzinga.com